Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H24N8O4S |
Molecular Weight | 508.553 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=N1)C2=NC(N3CCOCC3)=C4SC(CN(C)C5=NC=C(C=N5)C(=O)NO)=CC4=N2
InChI
InChIKey=JOWXJLIFIIOYMS-UHFFFAOYSA-N
InChI=1S/C23H24N8O4S/c1-30(23-25-11-15(12-26-23)22(32)29-33)13-16-9-17-19(36-16)21(31-5-7-35-8-6-31)28-20(27-17)14-3-4-18(34-2)24-10-14/h3-4,9-12,33H,5-8,13H2,1-2H3,(H,29,32)
Molecular Formula | C23H24N8O4S |
Molecular Weight | 508.553 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.curis.com/pipeline/cudc-907Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22693356
Sources: http://www.curis.com/pipeline/cudc-907
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22693356
CUDC-907 is a small molecule inhibitor of histone deacetylase and PI3 kinase developed by Curis. It is investigated in clinical trials for the treatment of relapsed or refractory lymphomas, thyroid cancer, multiple myeloma, breast cancer and other malignancies.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL325 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22693356 |
1.7 nM [IC50] | ||
Target ID: CHEMBL1829 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22693356 |
1.8 nM [IC50] | ||
Target ID: CHEMBL5103 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22693356 |
2.8 nM [IC50] | ||
Target ID: P42336 Gene ID: 5290.0 Gene Symbol: PIK3CA Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/22693356 |
19.0 nM [IC50] | ||
Target ID: O00329 Gene ID: 5293.0 Gene Symbol: PIK3CD Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/22693356 |
39.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9.19 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28860342 |
60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CUDC-907 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
24.5 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28860342 |
60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CUDC-907 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.89 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28860342 |
60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CUDC-907 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27049457
The recommended dose for phase 2 clinical trial is 60 mg on the 5/2 dosing schedule.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22693356
Human cancer cell lines were purchased from American Type Culture Collection (Manassas, VA) and plated at densities of 5,000 to 10,000 per well in 96-well flat-bottomed plates with the recommended culture medium. The cells were then incubated with compounds at various concentrations for 72 hours in culture medium supplemented with 0.5% (v/v) FBS. Growth inhibition was assessed by assay of cellular ATP content using the Perkin-Elmer ATPlite kit. CUDC-907 inhibits the growth of cell lines with IC50 of 10-100 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:32:50 GMT 2025
by
admin
on
Mon Mar 31 23:32:50 GMT 2025
|
Record UNII |
3S9RX35S5X
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C129825
Created by
admin on Mon Mar 31 23:32:50 GMT 2025 , Edited by admin on Mon Mar 31 23:32:50 GMT 2025
|
||
|
NCI_THESAURUS |
C1404
Created by
admin on Mon Mar 31 23:32:50 GMT 2025 , Edited by admin on Mon Mar 31 23:32:50 GMT 2025
|
||
|
NCI_THESAURUS |
C1946
Created by
admin on Mon Mar 31 23:32:50 GMT 2025 , Edited by admin on Mon Mar 31 23:32:50 GMT 2025
|
||
|
FDA ORPHAN DRUG |
467814
Created by
admin on Mon Mar 31 23:32:50 GMT 2025 , Edited by admin on Mon Mar 31 23:32:50 GMT 2025
|
||
|
FDA ORPHAN DRUG |
482415
Created by
admin on Mon Mar 31 23:32:50 GMT 2025 , Edited by admin on Mon Mar 31 23:32:50 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID90712307
Created by
admin on Mon Mar 31 23:32:50 GMT 2025 , Edited by admin on Mon Mar 31 23:32:50 GMT 2025
|
PRIMARY | |||
|
DE-36
Created by
admin on Mon Mar 31 23:32:50 GMT 2025 , Edited by admin on Mon Mar 31 23:32:50 GMT 2025
|
PRIMARY | |||
|
10504
Created by
admin on Mon Mar 31 23:32:50 GMT 2025 , Edited by admin on Mon Mar 31 23:32:50 GMT 2025
|
PRIMARY | |||
|
100000181111
Created by
admin on Mon Mar 31 23:32:50 GMT 2025 , Edited by admin on Mon Mar 31 23:32:50 GMT 2025
|
PRIMARY | |||
|
DB11891
Created by
admin on Mon Mar 31 23:32:50 GMT 2025 , Edited by admin on Mon Mar 31 23:32:50 GMT 2025
|
PRIMARY | |||
|
1339928-25-4
Created by
admin on Mon Mar 31 23:32:50 GMT 2025 , Edited by admin on Mon Mar 31 23:32:50 GMT 2025
|
PRIMARY | |||
|
3S9RX35S5X
Created by
admin on Mon Mar 31 23:32:50 GMT 2025 , Edited by admin on Mon Mar 31 23:32:50 GMT 2025
|
PRIMARY | |||
|
54575456
Created by
admin on Mon Mar 31 23:32:50 GMT 2025 , Edited by admin on Mon Mar 31 23:32:50 GMT 2025
|
PRIMARY | |||
|
CHEMBL3545052
Created by
admin on Mon Mar 31 23:32:50 GMT 2025 , Edited by admin on Mon Mar 31 23:32:50 GMT 2025
|
PRIMARY | |||
|
C104008
Created by
admin on Mon Mar 31 23:32:50 GMT 2025 , Edited by admin on Mon Mar 31 23:32:50 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR |
CUDC-907 is a dual PI3K.ALPHA. and HDAC1 inhibitor. Phase 1.
INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR |
CUDC-907 is a dual PI3K.ALPHA. and HDAC2 inhibitor. Phase 1.
INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR |
CUDC-907 is a dual PI3K.ALPHA. and HDAC3 inhibitor. Phase 1.
INDUCER
IC50
|
||
|
TARGET -> INHIBITOR |
CUDC-907 is a dual PI3K.ALPHA. and HDAC10 inhibitor. Phase 1.
INHIBITOR
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |